OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← Melanoma Focus

2025-01-31-accounts

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

Registered number: 06057181 Charity number: 1124716

MELANOMA FOCUS

(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2025

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

CONTENTS

Page
Reference and Administrative Details of the Charity, its Trustees and Advisers 1 - 2
Trustees' Report 3 - 8
Independent Examiner's Report 9 - 10
Statement of Financial Activities 11
Balance Sheet 12 - 13
Statement of Cash Flows 14
Notes to the Financial Statements 15 - 31

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 JANUARY 2025

Trustees Mrs Imogen Cheese
Dr Phillippa Gail Corrie (resigned 6 December 2024)
Dr Mark Harries
Professor Catherine Anne Harwood
Mrs Jacqueline Anne Hodgetts
Professor Paul Nathan (resigned 14 June 2024)
Mr Alan Howard Skyrme Peach
Professor Samra Turajlic (resigned 3 April 2025)
Hugh William Munro (appointed 11 September 2024)
George Ulmann (appointed 11 September 2024)
Kayley Dempsey (appointed 11 September 2024)
Carl Horrobin (appointed 11 September 2024)
Caroline Stevens (appointed 11 September 2024)
Dr Miranda Payne (appointed 5 September 2025)
Company registered
number
06057181
Charity registered
number
1124716
Registered office
Salisbury House
Station Road
Cambridge
CB1 2LA
Chief executive officer
Ms Susanna Daniels
Independent Examiner
M Hewett FCA DChA
Peters Elworthy & Moore
Chartered Accountants
Salisbury House
Station Road
Cambridge
CB1 2LA
Bankers
NatWest
11 Western Boulevard
Bede Island
Leicester
LE2 7EJ
HSBC UK
53 High Street
Newmarket
Suffolk
CB8 8NF

Page 1

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

Solicitors

Withers LLP 20 Old Bailey London EC4M 7AN

Page 2

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 JANUARY 2025

The Trustees present their annual report together with the financial statements of the Company for the year 1 February 2024 to 31 January 2025. The annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

OBJECTIVES AND ACTIVITIES

Policies and objectives

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

The objects of Melanoma Focus as set out in its Memorandum of Association (as amended by special resolution on 5 July 2023) are to:

  1. to promote research into the causes and the treatment of melanoma for the public benefit; and

  2. to raise awareness and advance education in relation to melanoma and its prevention, both to the general public and within the medical and scientific community, by:

  3. producing, collecting, maintaining, and disseminating information and materials about the disease, its treatment, the minimisation of risk in relation to it, and its prevention; and

  4. supporting the development of clinical guidelines and consensus positions about the treatment of all forms of melanoma, and improving the efficiency, skill, and knowledge of health professionals working in the melanoma field.

Melanoma is the fifth most common cancer in the UK, with around 17,500 new melanoma cases in the UK every year, or 48 every day. It is the deadliest form of skin cancer, however, the outlook for people with advanced melanoma is improving due to significant advances in melanoma medicine. About 10-15 years ago there was little that could be done to improve the survival of those with advanced disease; now there are a range of options, including immunotherapy treatments which are having a transformative effect. These treatments are now licensed and approved for use beyond advanced and metastatic melanomas. Yet it is surprising to reflect that each year more people die from skin cancer in the UK than in Australia.

The charity aims to improve the knowledge and understanding of all aspects of melanoma. The charity’s objectives in achieving this aim include: creating reliable and trusted information resources leading to a better understanding of the disease, its treatment options supporting patients and their families; organising the annual Melanoma Patient Conference; raising awareness of melanoma supporting the general public; organising the largest multidisciplinary accredited educational meetings for clinicians, scientists and others in the healthcare sector; acting as a professional membership organisation for everyone working in the melanoma field in the UK; campaigning and contributing to national debates; and raising money to fund research projects for patient benefit.

Page 3

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

ACHIEVEMENTS AND PERFORMANCE

Review of activities

Melanoma Focus's work focuses on 3 pillars:

  1. Supporting patients and carers

  2. Supporting healthcare professionals

  3. Raising awareness of melanoma and campaigning.

86% of melanomas are preventable by staying safe in the sun and avoiding sunbeds. It is known from research in Australia that repeated campaigns are required to change behaviours and therefore the charity’s annual national awareness programmes, particularly during Melanoma Awareness Month of May are a critical element of the charity’s activities. In 2024, Melanoma Focus executed a poster and digital campaign across 123 UK service stations, commissioned independent research which showed that 28% of UK adults are using sunbeds, a known risk factor for melanoma and the media coverage from the survey data culminated in 349 pieces of media coverage with a reach of over 124 million. Melanoma Focus 2023 survey data showed that 67% would use more sunscreen if it was 20% cheaper and 10% said that they didn’t use sunscreen because of the cost. Sunscreen should not be considered a luxury item, but an essential healthcare product. This led to the charity commissioning and publishing in 2024 a health economic report examining the impact of zero-rated VAT on factor 30+ sunscreens which demonstrated that this could save the NHS over £128 million in treatment costs outweighing the annual revenue lost at £67 million. Importantly, 2,500 – 3,200 cases of melanoma cases could be prevented annually.

Melanoma Focus worked with ITN Business to launch a series of podcasts covering some important topics including the importance of protecting all skin tones, melanoma myths and prevention and living beyond a melanoma diagnosis. Melanoma Focus additionally raised awareness and celebrated diversity at the Brighton and Hove Pride LGBTQ+ Community Parade to over 300,000 spectators.

Melanoma Focus was reaccredited by PIF TICK as a trusted patient information provider. Collaborating with healthcare professionals and patients, the charity actively reviews and updates the patient information within the Melanoma Stages & Treatment Guide.

The annual 2024 Melanoma Patient Conference welcomed 223 patients and support persons. This important event is designed to empower patients to take an active role in their care. Patients and their loved ones are able to network in a safe space while learning about the latest developments in melanoma medicine.

The Melanoma Helpline, a confidential, free service supporting anyone with a worry or concern about melanoma is manned by eight expert skin cancer clinical nurse specialists. The Helpline service is considered a lifeline to many. Feedback from questionnaires is incredibly positive and 2024 data showed that 100% of users would recommend the service to friends and family.

The charity continues to organise two CME accredited meetings each year; one virtual and one face-to-face providing options for busy medical teams to be educated by eminent national and international experts as well as network with colleagues. Feedback from each meeting is collated, reviewed and is resoundingly positive and from May 2024:

98% rated the scientific programme as excellent or good (82% excellent) 97% stated that the meeting would definitely or possibly impact on their future practice (70% definitely) 99% would definitely or possibly recommend the meeting to their colleagues (97% definitely).

Melanoma Focus continues to actively respond to NICE technology appraisals and appeals and SMC assessments of melanoma treatments as a medical and patient stakeholder.

Page 4

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

As part of the commitment to provide information and resources on rare melanomas, Melanoma Focus assembled a Guidelines Development Group which was NICE-accredited (before NICE closed its accreditation programme in July 2024) to review and update the ano-urogenital mucosal melanoma guidelines.

To support medical teams and patients, guidelines to support skin side-effects from immunotherapy treatment are underway.

Melanoma Focus is committed to commission, fund, support and promote research into the wide field of melanoma for patient benefit. Regular calls for proposals are invited and in 2024, two new projects were approved. Melanoma Focus ensures that their unique Melanoma TrialFinder is kept up to date with its two portals; one to give patients information and an understanding of clinical trials to discuss with their medical teams and a clinician version. Melanoma Focus continues to work with an increasing number of Trial Management Groups to support the development and review of UK clinical trials.

With the closure of the UK National Cancer Research Institute (NCRI), Melanoma Focus are providing administrative support to permit the work of the skin group to continue comprising work in both melanomas and non-melanoma skin cancers with the formation of the UK Skin Cancer Clinical Trial Group.

FINANCIAL REVIEW

Going Concern

The Trustees have reviewed the financial position of the charity and have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the financial statements continue to be prepared on the going concern basis.

Reserves Policy

At the end of the year there were reserves of £298,740 (2024: £334,053) of which £28,379 was restricted and £270,361 was unrestricted. The charity’s income is mainly derived from donations and discretionary sponsorship.

The Trustees aim to maintain free reserves in unrestricted funds at a desired level of £200,000, with a minimum necessary of £180,000. This level is considered prudent given the charities’ increased income and subsequent movement into the classification of a large charity, to ensure the charity remains in a position to support its current commitments over the next few years, as well as able to embark on our other planned initiatives. At the year end the charity had free reserves of £264,979 (2024: £245,222).

A cautious attitude will be maintained, especially over expenditure on indirect costs, and the Trustees will continue to review the level of free reserves periodically.

Results for the year

As previously, the wide range of events and initiatives in which Melanoma Focus takes part accounted for a significant proportion of our income. Melanoma Focus received donations and grants totalling £300,272 (2024: £293,830) as well as membership subscriptions and income from the Focus and Regional meetings of £71,511 (2024: £59,015). Corporate sponsorship income was £125,000 (2024: £188,750).

The charity spent £37,164 (2024: £48,191) on raising funds. Direct expenditure on the charity's main projects was £373,141 (2024: £325,612). Total expenditure amounted to £537,511 (2024: £498,850) for the year, of which £136,364 (2024: £141,347) was met from restricted funds.

The net deficit for the year was £35,313 (2024: surplus of £47,415), which has decreased the charity's funds to £298,740, of which £28,379 was restricted and £270,361 was unrestricted.

Page 5

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

STRUCTURE, GOVERNANCE, AND MANAGEMENT

Constitution

Melanoma Focus is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association on 3 January 2008, with charity registration number 1124716. The current governing document is the Memorandum of Association (as amended by special resolution on 5 July 2023).

It was decided to change the official name of the charity from 'Melanoma Research Foundation Limited' to 'Melanoma Focus' – the name by which it is generally known – in all official and business contexts including registration with Companies House and the Charity Commission. This change was registered at Companies House on 25 August 2020.

Method of appointment or election of trustees

The company is the responsibility of the trustees who are elected in accordance with the terms in its Memorandum of Association. All directors of the company are also trustees of the charity, and there are no other trustees. The trustees named below served in the year. The board has the power to appoint additional trustees as it considers fit to do so based on their suitability for the role. A board skills audit was undertaken with a view to expand the skillset of the board.

The Trustees who served during the year were:

Mrs Imogen Cheese Dr Philippa Gail Corrie (resigned 6 December 2024) Dr Mark Harries Professor Catherine Anne Harwood Mrs Jacqueline Anne Hodgetts Professor Paul Nathan (resigned 17 June 2024) Mr Alan Howard Skyrme Peach Professor Samra Turajlic (resigned 3 April 2025) Mr Carl Horrobin (appointed 11 September 2024) Mr George Ulmann (appointed 11 September 2024) Mr Huge William Munro (appointed 11 September 2024) Mrs Caroline Stevens appointed 11 September 2024) Ms Kayley Dempsey (appointed 11 September 2024)

Organisational structure and decision-making

The charity's organisational structure consists of a board of Trustees, of which there were eight at the year end. The Board of Trustees meets three to four times a year to review the charity’s operations and strategy. At other times all Trustees are kept informed of issues affecting the charity and they contribute to making key decisions. The extent to which Trustees’ responsibilities for decisions affecting the development and operation of the charity are devolved, day to day, to the CEO is set out in the CEO’s contract of employment and terms of reference.

Benchmarks for remuneration of employees are taken from ACEVO (Association of Chief Executives of Voluntary Organisations ) and Cancer52 (an alliance of over 100 charities working in cancers outside the top 4 cancers) who both undertake annual pay and bonus surveys from their memberships.

Page 6

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

FUTURE ACTIVITIES

During 2025, significant activities and projects include:

Page 7

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The Trustees (who are also the directors of the Company for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on their behalf by:

................................................ Carl Horrobin Treasurer

Date: 30 October 2025

Page 8

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS (A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 JANUARY 2025

Independent Examiner's Report to the Trustees of Melanoma Focus ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 January 2025.

Responsibilities and Basis of Report

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Page 9

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2025

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: Dated: 30 October 2025

M Hewett FCA DChA Peters Elworthy & Moore

Chartered Accountants

Cambridge

Page 10

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 JANUARY 2025

Note
INCOME FROM:
Donations, grants and legacies
2
Charitable activities
3
Other trading activities
4
Investments
5
TOTAL INCOME
EXPENDITURE ON:
Raising funds
6
Charitable activities
7
TOTAL EXPENDITURE
NET INCOME/(EXPENDITURE)
Transfers between funds
13
NET MOVEMENT IN FUNDS
RECONCILIATION OF FUNDS:
Total funds brought forward
Net movement in funds
TOTAL FUNDS CARRIED FORWARD		 Unrestricted
funds
2025
£
289,455
70,773
94,424
2,991
457,643
37,164
363,983
401,147
56,496
(34,623)
21,873
248,488
21,873
270,361		 Restricted
funds
2025
£
10,817
738
33,000
-
44,555
-
136,364
136,364
(91,809)
34,623
(57,186)
85,565
(57,186)
28,379		 Total
funds
2025
£
300,272
71,511
127,424
2,991
502,198
37,164
500,347
537,511
(35,313)
-
(35,313)
334,053
(35,313)
298,740		 Total
funds
2024
£
293,830
59,015
190,325
3,095
546,265
48,191
450,659
498,850
47,415
-
47,415
286,638
47,415
334,053

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 15 to 31 form part of these financial statements.

Page 11

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS (A Company Limited by Guarantee) REGISTERED NUMBER: 06057181

BALANCE SHEET AS AT 31 JANUARY 2025

Note
FIXED ASSETS
Tangible assets
10
CURRENT ASSETS
Debtors
11
Cash at bank and in hand
CURRENT LIABILITIES
Creditors: amounts falling due within one
year
12
NET CURRENT ASSETS
TOTAL NET ASSETS
CHARITY FUNDS
Restricted funds
13
Unrestricted funds
13
TOTAL FUNDS		 60,922
280,070
340,992
(47,634)		 2025
£
5,382
5,382
293,358
298,740
28,379
270,361
298,740		 123,514
299,417
422,931
(92,144)		 2024
£
3,266
3,266
330,787
334,053
85,565
248,488
334,053

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

Page 12

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS (A Company Limited by Guarantee) REGISTERED NUMBER: 06057181

BALANCE SHEET (CONTINUED) AS AT 31 JANUARY 2025

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

................................................

Carl Horrobin

Treasurer

Date: 30 October 2025

The notes on pages 15 to 31 form part of these financial statements.

Page 13

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 JANUARY 2025

CASH FLOWS FROM OPERATING ACTIVITIES
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Dividends, interests and rents from investments
Purchase of tangible fixed assets
NET CASH (USED IN)/PROVIDED BY INVESTING ACTIVITIES
CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR
Cash and cash equivalents at the beginning of the year
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR
The notes on pages 15 to 31 form part of these financial statements		 2025
£
(18,816)
2,991
(3,522)
(531)
(19,347)
299,417
280,070		 2024
£
(63,586)
3,095
-
3,095
(60,491)
359,908
299,417

Page 14

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

1. ACCOUNTING POLICIES

1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Melanoma Focus meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

There were no significant estimates or judgements made by management in preparing these financial statements.

1.2 GOING CONCERN

The Trustees have reviewed the financial position of the charity, and have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the financial statements continue to be prepared on the going concern basis.

1.3 FUND ACCOUNTING

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Page 15

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

1. ACCOUNTING POLICIES (CONTINUED)

1.4 INCOME

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Income from funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Meeting income is recognised in the period to which it relates. Income received in advance is carried forward as deferred income on the balance sheet. Any amounts owing to the charity for meetings which have occurred during the accounting period are included as debtors.

Membership income is recognised in the period in which it is received.

Grant income is recognised in the period to which it relates. Any income received in advance is carried forward as deferred income.

Donations raised through JustGiving and related gift aid are recognised in the period in which the income is transferred to the company's bank account. Other donations raised directly are recognised when receivable and the amount can be measured reliably by the charity.

Sponsorship income is recognised once the charity has received confirmation that the funding will be paid and the sum has been agreed, which may occur when a formal agreement is signed or may arise by a verbal or other written communication.

Page 16

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

1. ACCOUNTING POLICIES (CONTINUED)

1.5 EXPENDITURE

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Support costs are those incurred directly in support of the charitable activities and the general running of the charity.

Governance costs are those incurred in connection with administration of the charity, and to ensure compliance with constitutional and statutory requirements.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable on projects undertaken are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

1.6 TANGIBLE FIXED ASSETS AND DEPRECIATION

Tangible fixed assets costing £250 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings - 25% reducing balance
Computer equipment - 25% reducing balance
Website - 25% reducing balance

1.7 DEBTORS

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Page 17

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

1. ACCOUNTING POLICIES (CONTINUED)

1.8 CASH AT BANK AND IN HAND

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.9 PENSIONS

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

1.10 LIABILITIES AND PROVISIONS

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost.

1.11 FINANCIAL INSTRUMENTS

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Page 18

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

2. INCOME FROM DONATIONS, GRANTS AND LEGACIES

Unrestricted
funds
2025
£
Donations
266,455
Grants
23,000
289,455
TOTAL 2024
225,430		 Restricted
funds
2025
£
817
10,000
10,817
68,400		 Total
funds
2025
£
267,272
33,000
300,272
293,830		 Total
funds
2024
£
222,830
71,000
293,830

3. INCOME FROM CHARITABLE ACTIVITIES

Unrestricted
funds
2025
£
Membership fees
7,385
Focus on Melanoma meeting income
44,998
Regional meeting income
18,390
Patient Conference
-
70,773
TOTAL 2024
51,054		 Restricted
funds
2025
£
-
-
-
738
738
7,961		 Total
funds
2025
£
7,385
44,998
18,390
738
71,511
59,015		 Total
funds
2024
£
4,260
30,009
16,785
7,961
59,015

Page 19

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

4. INCOME FROM OTHER TRADING ACTIVITIES

Income from fundraising events

Unrestricted
funds
2025
£
Sales of merchandise
2,424
TOTAL 2024
1,575
Income from sponsorships
Unrestricted
funds
2025
Restricted
funds
2025
£
£
Corporate sponsorship for Focus on
Melanoma meetings
68,000
-
Corporate sponsorship for Regional meetings
24,000
-
Sponsorship for Awareness campaign
-
20,000
Sponsorship for Patient Conference
-
13,000
92,000
33,000
TOTAL 2024
132,000
56,750		 Total
funds
2025
£
2,424
1,575
Total
funds
2025
£
68,000
24,000
20,000
13,000
125,000
188,750		 Total
funds
2024
£
1,575
Total
funds
2024
£
74,000
42,400
29,600
42,750
188,750

5. INVESTMENT INCOME

Unrestricted
funds
2025
£
Deposit account interest
2,991
TOTAL 2024
3,095		 Total
funds
2025
£
2,991
3,095		 Total
funds
2024
£
3,095

Page 20

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

6. EXPENDITURE ON RAISING FUNDS

COSTS OF RAISING VOLUNTARY INCOME

Unrestricted
funds
2025
£
Fundraising Activities
15,023
Fundraising Officer
22,141
37,164
TOTAL 2024
48,191		 Total
funds
2025
£
15,023
22,141
37,164
48,191		 Total
funds
2024
£
10,697
37,494
48,191

7. ANALYSIS OF CHARITABLE EXPENDITURE

Charitable activities
TOTAL 2024		 Activities
undertaken
directly
2025
£
373,141
325,612		 Support
costs
2025
£
127,206
125,047		 Total
funds
2025
£
500,347
450,659		 Total
funds
2024
£
450,659

In 2024 £141,347 of charitable expenditure was met from restricted funds with the balance met from unrestricted funds.

Page 21

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

7. ANALYSIS OF CHARITABLE EXPENDITURE (CONTINUED)

ANALYSIS OF DIRECT COSTS

Staff costs
Depreciation and loss on disposal of fixed assets
Melanoma database project
Meeting costs
Research projects
Helpline
PDA / MPG project
Patient Conference
Awareness and Policy work
TOTAL 2024		 Charitable
activities
2025
£
173,236
1,406
(17,500)
52,339
40,000
2,950
275
48,966
71,469
373,141
325,612		 Total
funds
2025
£
173,236
1,406
(17,500)
52,339
40,000
2,950
275
48,966
71,469
373,141
325,612		 Total
funds
2024
£
156,582
1,090
(15,000)
62,140
1,582
2,838
7,983
40,062
68,335
325,612

Helpline restricted fund expenditure of £33,154 is comprised of £2,950 (2024: £2,838) direct costs as above, and £30,204 (2024: £37,129) allocated staff costs.

Page 22

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

7. ANALYSIS OF CHARITABLE EXPENDITURE (CONTINUED)

ANALYSIS OF SUPPORT COSTS

Rent
Bank charges
Insurance
Postage and stationery
Advertising and promotion
IT services and supplies
Professional fees and costs
Legal fees (governance)
Accountancy fees (governance)
Irrecoverable VAT
TOTAL 2024		 Charitable
activities
2025
£
1,600
1,670
2,125
10,979
6,442
7,722
59,921
-
14,491
22,256
127,206
125,047		 Total
funds
2025
£
1,600
1,670
2,125
10,979
6,442
7,722
59,921
-
14,491
22,256
127,206
125,047		 Total
funds
2024
£
1,360
1,562
1,643
6,468
8,006
5,335
40,923
3,421
14,854
41,475
125,047

Irrecoverable VAT represents adjustments for historic amounts owed regarding VAT due on sponsorship income.

8. INDEPENDENT EXAMINER'S REMUNERATION

2025 2024
£ £
Fees payable to the Charity's independent examiner in respect of:
Independent examination of the Company's annual accounts 3,400 3,250
Other accountancy services 11,091 11,604

Page 23

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

9. STAFF COSTS

Wages and salaries
Social security costs
Contribution to defined contribution pension schemes		 2025
£
177,256
11,244
6,877
195,377		 2024
£
180,478
10,405
3,193
194,076

The average number of persons employed by the Charity during the year was as follows:

2025 2024
No. No.
Charitable activities 5 4

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

2025 2024
No. No.
In the band £60,001 - £70,000 - 1

The key management personnel of the charity comprises the Trustees and the CEO. The trustees all give their time and expertise without any kind of remuneration or other benefit in kind (2024: £Nil). The remuneration of the CEO was £70,752 in the year, including employer's costs (2024: £70,280).

Page 24

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

10. TANGIBLE FIXED ASSETS

COST
At 1 February 2024
Additions
At 31 January 2025
DEPRECIATION
At 1 February 2024
Charge for the year
At 31 January 2025
NET BOOK VALUE
At 31 January 2025
At 31 January 2024		 Fixtures and
fittings
£
524
-
524
466
18
484
40
58		 Computer
equipment
£
9,296
3,522
12,818
6,291
1,267
7,558
5,260
3,005		 Website
£
2,840
-
2,840
2,637
121
2,758
82
203		 Total
£
12,660
3,522
16,182
9,394
1,406
10,800
5,382
3,266

Page 25

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

11. DEBTORS

DUE WITHIN ONE YEAR
Trade debtors
Other debtors
Prepayments and accrued income		 2025
£
2,719
6,869
51,334
60,922		 2024
£
49,487
5,000
69,027
123,514

12. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Trade creditors
Other taxation and social security
Project commitments
Accruals and deferred income
DEFERRED INCOME
Deferred income at 1 February 2024
Resources deferred during the year
Amounts released from previous periods		 2025
£
16,746
550
26,043
4,295
47,634
2025
£
5,340
-
(5,340)
-		 2024
£
24,231
14,590
42,500
10,823
92,144
2024
£
2,570
5,340
(2,570)
5,340

Deferred income relates to meeting income received in advance.

Page 26

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

13. STATEMENT OF FUNDS

STATEMENT OF FUNDS - CURRENT YEAR

UNRESTRICTED FUNDS
Unrestricted Funds
RESTRICTED FUNDS
PDA/MPG project
Melanoma Helpline
Melanoma Awareness activities
National Melanoma Database
project
Patient Conference
TOTAL OF FUNDS		 Balance at 1
February
2024
£
248,488
1,016
-
-
57,500
27,049
85,565
334,053		 Income
£
457,643
-
10,000
10,000
-
24,555
44,555
502,198		 Expenditure
£
(401,147)
(275)
(33,154)
(71,469)
17,500
(48,966)
(136,364)
(537,511)		 Transfers
in/out
£
(34,623)
-
23,154
61,469
(50,000)
-
34,623
-		 Balance at
31 January
2025
£
270,361
741
-
-
25,000
2,638
28,379
298,740

PDA/MPG project - Supported by a number of grants, the PDA/MPG (Melanoma Patient Guide) project allowed the charity to review and overhaul the charity’s patient information including the creation of various videos and animations.

Melanoma Helpline - The Melanoma Helpline is manned by experienced skin cancer nurses and support anyone with a concern about melanoma. The service is constantly being monitored and expands according to demand.

Melanoma Awareness activities - Melanoma Focus is committed to raising awareness of melanoma as it is a largely preventable cancer. The majority of the activities fall within Melanoma Awareness Month of May and resources are created for the Summer months.

National Melanoma Database project - The National Melanoma Database project under the Melanoma Focus umbrella was previously closed to future sites being set up after an internal and external review due to large scale IT projects outside of the NHS being extremely challenging. The database continues to run in three hospitals and a further hospital is in set up. Some restricted funds remain to support various final payments and a data review of three sites with the consideration of writing up the research. The transfer represents the reversal of a previously expected cost that will no longer be incurred.

Transfers from unrestricted to restricted funds are made where spend for certain activities is in excess of the original income.

Page 27

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

13.
STATEMENT OF FUNDS (CONTINUED)
STATEMENT OF FUNDS - PRIOR YEAR
Balance at
1 February
2023
£
UNRESTRICTED FUNDS
Unrestricted Funds
219,138
RESTRICTED FUNDS
PDA/MPG project
-
Melanoma Helpline
-
Melanoma Awareness activities
-
National Melanoma Database
project
67,500
Patient Conference
-
67,500
TOTAL OF FUNDS
286,638		 Income
£
413,154
9,000
17,500
39,500
-
67,111
133,111
546,265		 Expenditure
£
(357,503)
(7,984)
(39,966)
(68,335)
15,000
(40,062)
(141,347)
(498,850)		 Transfers
in/out
£
(26,301)
-
22,466
28,835
(25,000)
-
26,301
-		 Balance at
31 January
2024
£
248,488
1,016
-
-
57,500
27,049
85,565
334,053

Page 28

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

14. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT PERIOD

Unrestricted
funds
2025
£
Tangible fixed assets
5,382
Current assets
287,613
Creditors due within one year
(22,634)
TOTAL
270,361
ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR PERIOD
Unrestricted
funds
2024
£
Tangible fixed assets
3,266
Current assets
294,866
Creditors due within one year
(49,644)
TOTAL
248,488		 Restricted
funds
2025
£
-
53,379
(25,000)
28,379
Restricted
funds
2024
£
-
128,065
(42,500)
85,565		 Total
funds
2025
£
5,382
340,992
(47,634)
298,740
Total
funds
2024
£
3,266
422,931
(92,144)
334,053
Tangible fixed assets
Current assets
Creditors due within one year
TOTAL

Page 29

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

15.
RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW
ACTIVITIES
Net income/expenditure for the period (as per Statement of Financial
Activities)
ADJUSTMENTS FOR:
Depreciation charges
Dividends, interests and rents from investments
Decrease/(increase) in debtors
Increase/(decrease) in creditors
NET CASH USED IN OPERATING ACTIVITIES
16.
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash in hand
TOTAL CASH AND CASH EQUIVALENTS
17.
ANALYSIS OF CHANGES IN NET DEBT
At 1
February
2024
£
Cash at bank and in hand
299,417
299,417		 FROM OPERATING
2025
2024
£
£
(35,313)
47,415
1,406
1,090
(2,991)
(3,095)
62,592
(118,056)
(44,510)
9,060
(18,816)
(63,586)
2025
2024
£
£
280,070
299,417
280,070
299,417
Cash flows
At 31
January
2025
£
£
(19,347)
280,070
(19,347)
280,070

Page 30

Docusign Envelope ID: F5901DFB-878C-4D47-9D65-4CD49708F311

MELANOMA FOCUS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025

18. PENSION COMMITMENTS

The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge representing employer contributions payable by the company to the fund amounted to £6,877 (2024: £3,193). Contributions amounting to £1,043 were payable to the fund at the balance sheet date (2024: £Nil).

19. RELATED PARTY TRANSACTIONS

There were no related party transactions during the year other than disclosed in note 9.

Page 31